Bain Capital Public Equity Management LLC bought a new position in Five Prime Therapeutics Inc (NASDAQ:FPRX) in the 4th quarter, HoldingsChannel reports. The fund bought 38,272 shares of the biotechnology company’s stock, valued at approximately $839,000.
A number of other institutional investors have also recently added to or reduced their stakes in FPRX. Ark Investment Management LLC increased its holdings in Five Prime Therapeutics by 299.2% in the 2nd quarter. Ark Investment Management LLC now owns 14,174 shares of the biotechnology company’s stock worth $427,000 after acquiring an additional 10,623 shares in the last quarter. Parametric Portfolio Associates LLC grew its holdings in Five Prime Therapeutics by 140.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 23,894 shares of the biotechnology company’s stock valued at $719,000 after buying an additional 13,977 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Five Prime Therapeutics by 1.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,449 shares of the biotechnology company’s stock valued at $646,000 after buying an additional 397 shares in the last quarter. Nationwide Fund Advisors grew its holdings in Five Prime Therapeutics by 6.4% during the 3rd quarter. Nationwide Fund Advisors now owns 70,059 shares of the biotechnology company’s stock valued at $2,866,000 after buying an additional 4,208 shares in the last quarter. Finally, Dupont Capital Management Corp purchased a new stake in Five Prime Therapeutics during the 3rd quarter valued at approximately $341,000. 74.94% of the stock is owned by institutional investors.
Shares of Five Prime Therapeutics Inc (NASDAQ FPRX) opened at $19.23 on Tuesday. Five Prime Therapeutics Inc has a fifty-two week low of $17.01 and a fifty-two week high of $48.87. The stock has a market cap of $670.37, a P/E ratio of -4.36 and a beta of 3.33.
A number of equities research analysts have issued reports on the stock. Zacks Investment Research lowered shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 2nd. BMO Capital Markets cut their price objective on shares of Five Prime Therapeutics from $75.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 28th. Nomura cut their price objective on shares of Five Prime Therapeutics from $94.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, February 28th. BidaskClub lowered shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, February 5th. Finally, ValuEngine lowered shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Three equities research analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $47.20.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/03/13/bain-capital-public-equity-management-llc-buys-shares-of-38272-five-prime-therapeutics-inc-fprx.html.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.
Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics Inc (NASDAQ:FPRX).
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.